PCH
CTNM

Polar Capital Holdings’s Contineum Therapeutics CTNM Stock Holding History

Polar Capital Holdings’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,604
Closed -$639K – 321
2024
Q4 		$639K Sell
43,604
-172,997
-80% -$2.74M ﹤0.01% 285
2024
Q3 		$4.15M Buy
216,601
+2,159
+1% +$41.4K 0.02% 248
2024
Q2 		$3.78M Buy
+214,442
New +$3.45M 0.02% 237

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

Polar Capital Holdings's CTNM Position: Q1 2025 in Review

Polar Capital Holdings sold out of Contineum Therapeutics (CTNM) in Q1 2025, closing a stake of 43,604 shares — an estimated $639K sold.

Polar Capital Holdings first reported a position in CTNM in Q2 2024 and held it in 3 quarters. The position peaked at $4.15M in Q3 2024. 63 funds tracked by Wall St. Rank hold CTNM as of Q1 2025.

  • Polar Capital Holdings reported no remaining Contineum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 43,604 Contineum Therapeutics shares in Q1 2025, an estimated $639K.
  • Polar Capital Holdings first reported a position in Contineum Therapeutics in Q2 2024 and held it in 3 quarters.
  • Polar Capital Holdings's Contineum Therapeutics position peaked at $4.15M in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2025.

Based on Polar Capital Holdings's 13F filing for Q1 2025, filed 15 May 2025.